Using natural products to target a specific protein in prostate cancer treatment
Official title: Nautral products for targeting Skp2 in cancer interception
Funded at University of California-Irvine · NIH-11099931 · Data updated 2026-11-12
This study is looking at how natural products can help men with prostate cancer by targeting a specific protein that might make the cancer worse, with the goal of finding gentle treatment options for those who are being monitored or have already had surgery or radiation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | June 1, 2024 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $333,625 |
| NIH project number | 5UG3CA290368-02 |
| Project ID | NIH-11099931 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are American men diagnosed with prostate cancer, particularly those under active surveillance or those who have undergone treatment.
✕Less likely to help
Patients with advanced prostate cancer who require immediate aggressive treatment may not benefit from this research.
What this research studies
This research focuses on prostate cancer, which is a common cancer among American men. It aims to identify natural products that can target Skp2, a protein that may play a role in the progression of prostate cancer. The study will explore how these natural agents can prevent cancer progression during active surveillance or after treatments like surgery or radiation. By targeting Skp2, the research seeks to provide low-toxicity options for patients who may be at risk of aggressive disease.
Why it matters
Potential benefit: If successful, this research could lead to new, less toxic treatment options for prostate cancer patients, improving their quality of life.
How similar studies have gone: Previous research has shown promise in targeting similar proteins in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Zi, Xiaolin — University of California-Irvine
- Study coordinator: Zi, Xiaolin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.